Clinical Trials in Atlanta

Showing 9261-9280 of 19,805 trials

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

NCT04166630

The goal of this study is to develop a non-invasive test to diagnose intensive care unit (ICU) acquired weakness that can be administered to both responsive and non-responsive patients. Study participation will involve the measurement of muscle fatigue during a single 30 minute session. Skeletal muscle will be stimulated with an FDA approved clinical electrical stimulator and accelerations will be passively recorded with an accelerometer.

ICU Acquired Weakness

Emory University22 participantsStarted Feb 2021

Atlanta, Georgia, United States

COMPLETEDPhase 3< 1 mile

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212

Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients.

Axial SpondyloarthritisNonradiographic Axial SpondyloarthritisNr-axSpA

UCB BIOSCIENCES GmbH317 participantsStarted Sep 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Tucson, Arizona, United States +102 more locations

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Find Trials by Condition in Atlanta

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Soccer-based Adaptation of the Diabetes Prevention Program

Canagliflozin-Mealtime Insulin Rescue

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease

Genomic Translation for Amyotrophic Lateral Sclerosis Care

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients